
GROWHAPPY LAUNCHES DURING ALLERGY AWARENESS WEEK TO HELP FAMILIES FEED ALLERGENS EARLY & OFTEN™
Groundbreaking line of Allergen ImmunoButters™ formulated by world-leading pediatric allergists help families get ahead of food allergies
AUSTIN, Texas, May 12, 2025 /PRNewswire/ — Just in time for Allergy Awareness Week (May 11–17, 2025), GrowHappy® is proud to launch its groundbreaking line of Allergen ImmunoButters™—nutrient-packed spreads formulated to help families get allergens into their child's diet Early & Often™. Research shows that early introduction of allergens in the first year of life, ideally as early as 4-6 months of age, and keeping them in the diet is an effective way to train the immune system while it is still developing. Created and co-founded by world's top pediatric allergy experts, GrowHappy strives to help families find food freedom.
Grounded in cutting-edge research and guided by world-renowned allergy experts, GrowHappy makes early allergen introduction safe, simple, and nourishing. The U.S. Department of Agriculture (USDA) recommends introducing potentially allergenic foods when other complementary foods are introduced to an infant's diet. The American Academy of Pediatrics also supports that we should not delay the introduction of allergenic foods once the baby is eating.
'Leading allergy experts and pediatricians agree – feed allergens Early & Often from 4 months to train the immune system, when developmentally appropriate,' says Professor George du Toit, pediatric allergist, author of LEAP and EAT-On studies – and founding member of GrowHappy's ImmunoNutrition Squad.
GrowHappy is launching with five key allergen snacks: Egg, Peanut, Walnut, Cashew, and Sesame. Designed for versatility, the Allergen ImmunoButters™ can be mixed into breastmilk, formula, water, yogurt, oatmeal, or a smoothie, spread on toast, or enjoyed straight from the packet with a spoon. Each allergen snack is packed with 2-4 unique fruits and/or vegetables with 16 plant-based foods across the range. GrowHappy calls it ImmunoNutrition: Precise doses of simple and varied ingredients fed Early & Often™ to open up a world of food.
Available through a monthly subscription box, GrowHappy helps parents consistently feed allergens Early & Often™ through the early years of childhood with LEAP-aligned doses to train the immune system that allergens are just nutritious foods, and that there is no need for the immune system to go on overdrive. GrowHappy also helps families offer a diverse range of plant-based foods which support a healthy gut microbiome.
'We can train the immune system while it's still developing,' says Professor David Fleischer, with Professor Carina Venter adding, 'GrowHappy is all about nourishing the immune system and promoting a healthy gut microbiome.'
Founded by Stephanie Wibom, a mother who refused to accept that her daughter would live a life limited by food allergies, GrowHappy is her mission in motion. After her daughter had an allergic reaction, she sought answers from top allergy experts. She learned that the allergens she once feared were actually a big part of the solution. Over time, her family found food freedom without any food allergies. With the guidance of GrowHappy's internationally recognized pediatric allergy experts, with whom she co-founded the company, GrowHappy is grounded in research and powered by purpose.
The GrowHappy ImmunoNutrition Squad includes the world's leading allergy researchers and clinicians, who have written many of the most important studies on food allergies:
Professor George du Toit – Author of LEAP & EAT-On studies, King's College London Dr. Sharon Chinthrajah – Co-Director of Stanford University's Sean N. Parker Center for Allergy Research Professor Carina Venter – Author of European, American and Canadian allergy prevention guidelines Dr. Edwin Kim – Director of the UNC Food Allergy Initiative Professor David Fleischer – Division Chief of Allergy & Immunology at Children's Hospital Colorado Dr. Douglas Mack – VP of Canadian Society of Allergy and Clinical Immunology
GrowHappy will help millions of parents take control of their children's futures and empower them to bravely feed towards food freedom and happy gut microbiomes.
The Food Allergy Epidemic:
More than 30 million Americans have food allergies 2 kids in every US classroom has a food allergy and 10% of adults are affected Nut allergies have doubled since the late 80s 40% of kids experience life-threatening reactions at least once $25 billion is lost in annual U.S. family income due to food allergies
What Makes GrowHappy Special:
Co-founded by world-leading allergy experts Consistent 2g LEAP-aligned doses across all allergens, designed by the LEAP author 7 allergens addressed early to maximize critical window REAL FOOD approach — no powders, not ultra-processed All allergens split out for ease, peace of mind, and flexibility Teaches tastes of allergens so baby learns to like them Supports gut health and diet diversity with 16 plant-based ingredients Yummy snacks in nut and seed butter formats
Feed early, feed often, feed real food and help empower a brave world of food freedom!
Learn more and subscribe at letsgrowhappy.com. Follow along @letsgrowhappy on Instagram and TikTok, @letsgrowhappynow on Facebook, and LinkedIn
ABOUT GROWHAPPYGrowHappy and its founding team of world-renowned allergy experts are on a mission to empower a brave world of food freedom through science-backed nutrition. Created by leading pediatric allergists, researchers, and a mom who bravely fed allergens Early & Often™ until there were no food allergies, GrowHappy's Allergen ImmunoButters™ are a first-of-their-kind innovation – and they're delicious, nutritious and foster happy gut microbiomes.
MEDIA CONTACT: Birn Communications Jen@jenbirn.com (646) 206-1130
GrowHappy®, a groundbreaking line of Allergen ImmunoButters™ has launched just in time for Allergy Awareness Week (May 11–17, 2025). @LetsGrowHappy are nutrient-packed spreads formulated to help families get allergens into their child's diet Early & Often™. Research shows that early introduction of allergens in the first year of life, ideally as early as 4-6 months of age, and keeping them in the diet is an effective way to train the immune system while it is still developing. Created and co-founded by the world's top pediatric allergy experts, GrowHappy strives to help families find food freedom.
Follow them on Instagram @LetsGrowHappy for more
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
11 hours ago
- Malaysian Reserve
Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034)
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs and emerging BTK inhibitors, which offer targeted, high-efficacy options, especially for progressive forms with limited existing therapies. LAS VEGAS, June 11, 2025 /PRNewswire/ — Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath surrounding nerves in the brain and spinal cord. This interference disrupts the flow of signals between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision disturbances, and difficulty with mobility. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The therapeutic landscape for multiple sclerosis has undergone a significant transformation, spurred by progress in both drug-based and supportive treatment approaches. Although MS remains without a cure, the market is seeing an expanding array of disease-modifying therapies (DMTs), greater personalization of care, and innovations in how treatments are delivered—all aimed at enhancing patient outcomes and quality of life. Pharmacologically, multiple sclerosis treatment involves both immediate and long-term strategies. For managing acute relapses, high-dose intravenous corticosteroids, most commonly methylprednisolone, continue to be the primary treatment, usually given over 3 to 5 days and followed by a course of tapering oral steroids. Learn more about the multiple sclerosis therapeutics market @ Multiple Sclerosis Drugs Market Intravenous corticosteroids, such as methylprednisolone, are effective for treating acute multiple sclerosis relapses but do not impact the long-term course of the disease. Ongoing disease management relies on disease-modifying therapies (DMTs), selected based on the severity of MS and individual patient requirements, to reduce relapse frequency and delay disability progression. While older injectable multiple sclerosis treatments like PLEGRIDY are still used, newer oral options like MAYZENT, VUMERITY, and MAVENCLAD provide greater convenience and may improve patient adherence. High-efficacy monoclonal antibodies (mAbs), including OCREVUS (now also available in a subcutaneous form), KESIMPTA, and BRIUMVI, are increasingly preferred for home-based therapy. Although LEMTRADA is a potent option, its use is restricted due to safety risks and its inclusion in the REMS program. As key multiple sclerosis drugs such as TYSABRI, TECFIDERA, AUBAGIO, and GILENYA face generic competition, pricing and access are being reshaped. In response, originator companies are shifting focus to next-generation treatments and improved formulations, such as subcutaneous versions and enhanced safety features, to retain market share. Supportive therapies also play a critical role; rehabilitation via exercise and physiotherapy can improve mobility and reduce fatigue, especially in progressive multiple sclerosis. Cognitive behavioral therapy (CBT) and mindfulness strategies help manage mood disorders like depression and anxiety, which in turn support treatment adherence. Additionally, lifestyle modifications involving diet, sleep hygiene, and vitamin D intake aid in symptom control. Assistive devices and occupational therapy further promote independence and enhance quality of life. Find out more on FDA-approved multiple sclerosis medication @ Multiple Sclerosis Treatments Multiple sclerosis treatment lacks neuroprotective and remyelinating therapies, with limited options for progressive multiple sclerosis. Current drugs focus on immune modulation but fail to reverse damage or halt progression. Diagnostic delays remain common due to nonspecific symptoms and limited biomarkers. There is a critical need for early detection tools, personalized therapies, and agents targeting neurodegeneration to improve outcomes in multiple sclerosis. The multiple sclerosis treatment pipeline remains robust, with promising candidates like Remibrutinib, Tolebrutinib, Fenebrutinib, and CNM-Au8 targeting novel mechanisms such as BTK inhibition and neuroprotection. Other multiple sclerosis drugs in the pipeline include Frexalimab (SAR441344) (Sanofi), Vidofludimus calcium (IMU-838) (Immunic Therapeutics), Masitinib (AB Science), PIPE-307 (Contineum Therapeutics), and others. These multiple sclerosis pipeline therapies reflect an increasing emphasis on progressive multiple sclerosis and remyelination to improve long-term outcomes. Discover which therapies are expected to grab major multiple sclerosis market share @ Multiple Sclerosis Treatment Market Tolebrutinib is an oral BTK inhibitor designed to penetrate the blood–brain barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025, the US FDA accepted tolebrutinib for priority review as a treatment for non-relapsing secondary progressive multiple sclerosis, to slow relapse-independent disability progression. A decision is anticipated by September 2025, with a parallel evaluation ongoing in the EU. Vidofludimus calcium is an investigational oral therapy currently in Phase III trials for relapsing multiple sclerosis and Phase II for progressive multiple sclerosis. It combines DHODH inhibition for immune regulation with Nurr1 activation for potential neuroprotective effects, aiming to target key mechanisms of neurodegeneration. In April 2025, Immunic reported positive outcomes from the Phase II CALLIPER trial, supporting vidofludimus calcium's role as a Nurr1 activator in progressive multiple sclerosis patients. Fenebrutinib is an innovative, oral, reversible, non-covalent BTK inhibitor in Phase III development for MS. By modulating both adaptive and innate immune responses via B cells and microglia, it offers a dual approach to controlling disease activity and slowing disability. It is currently the only reversible BTK inhibitor in late-stage multiple sclerosis trials. The Phase III program includes FENhance 1 and 2 studies in relapsing multiple sclerosis (vs. teriflunomide) and the FENtrepid trial in primary progressive multiple sclerosis (vs. ocrelizumab), marking the first head-to-head comparison of a BTK inhibitor with an approved PPMS therapy. Regulatory submissions for both RMS and PPMS are planned for 2026. In September 2024, Roche presented 48-week results from the FENopta Phase II open-label extension at the 40th ECTRIMS Congress. Remibrutinib is an oral covalent BTK inhibitor under investigation for multiple sclerosis and chronic spontaneous urticaria (CSU), where it blocks BTK signaling to prevent histamine release. While no Phase I or II trials have yet been conducted for multiple sclerosis, remibrutinib is in Phase III development for CSU through the REMODEL-1 and REMODEL-2 trials. Primary completion is expected in 2026, with regulatory submission anticipated in 2027. Earlier Phase IIb CSU data showed favorable safety and tolerability. CNM-Au8 is an oral gold nanocrystal therapy designed to address mitochondrial dysfunction in multiple sclerosis by boosting NAD+ production, enhancing antioxidant capacity, and activating the heat shock factor-1 pathway to support protein homeostasis. Although the VISIONARY-MS Phase II trial was halted early due to COVID-19, CNM-Au8 is being evaluated in the ongoing Phase II REPAIR-MS trial. Results from REPAIR-MS, along with a planned FDA End-of-Phase II meeting in 2025, will inform the design of a global Phase III trial. In April 2025, Clene Nanomedicine presented promising new data at the AAN Annual Meeting, showing meaningful improvements in cognition and visual function from the VISIONARY-MS open-label extension. Masitinib is being developed for progressive multiple sclerosis with a focus on inhibiting mast cells and microglia, key players in chronic neuroinflammation. This approach aims to slow progression in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (SPMS). Following positive results from a Phase IIb/III study, a confirmatory Phase III trial is ongoing. In September 2024, AB Science provided an update on masitinib's development at the ECTRIMS 2024 conference. Discover more about the multiple sclerosis pipeline @ Multiple Sclerosis Clinical Trials The anticipated launch of these emerging therapies for multiple sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the multiple sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for Multiple Sclerosis is expected to grow from USD 20 billion in the 7MM in 2024 at a 3.8% CAGR by 2034. This expansion across the 7MM will be driven by the introduction of innovative therapies, remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, and masitinib, among others. Furthermore, multiple sclerosis prevalence is rising due to modifiable environmental and lifestyle factors like Epstein-Barr virus, low vitamin D, smoking, obesity, and night shifts, with genetics and geography also contributing. DelveInsight's latest published market report, titled Multiple Sclerosis – Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the multiple sclerosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The multiple sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases of Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases of Multiple Sclerosis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM multiple sclerosis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this multiple sclerosis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the multiple sclerosis market. Also, stay abreast of the mitigating factors to improve your market position in the multiple sclerosis therapeutic space. Related Reports Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others. Relapsing-Remitting Multiple Sclerosis Market Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, among others Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, CinnaGen, Immunic, Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, GlaxoSmithKline, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:


Malaysian Reserve
a day ago
- Malaysian Reserve
9th Asia Agri-Tech Expo & Forum Opens Today, Driving Innovation in Asia-Pacific Agriculture
TAIPEI, June 11, 2025 /PRNewswire/ — Organised by Informa Markets Asia Ltd., the 2025 Asia Agri-Tech Expo & Forum officially opened today (June 11) at the ICC Tainan. The grand opening ceremony gathered key representatives from government, industry, academia, and research to witness a new milestone in the advancement of agri-tech in the Asia-Pacific region. Distinguished guests attending the ribbon-cutting ceremony included Mr. Michael Duck, Executive Vice President of Informa Markets Asia, Deputy Mayor Yeh Tse-Shan of Tainan City Government, President Su Chih-Fen of the National Animal Industry Foundation, along with numerous prominent figures from various sectors. This year's event features over 150 exhibitors from around the world, showcasing cutting-edge innovations in agriculture automation, smart livestock farming, precision irrigation, crop monitoring, and feed technology. In addition to the exhibition, the event presents 10 key themes across 60 professional seminars, offering in-depth discussions on emerging trends in agriculture, smart livestock farming, advanced feed technology, and biosecurity upgrades. The three-day exhibition is expected to attract over 25,000 visitors. With Tainan serving as a central hub for agriculture and aquaculture in southern Taiwan, the event provides an ideal platform for farmers, growers, and industry professionals to explore the latest advancements. Many exhibitors are launching new products on-site, including: TOTAL NUTRITION: Combining peptide protein, probiotics, and acidifiers to form the 'Golden Triangle' of gut health, achieving precise nutritional regulation and enhanced well-being. WONDER VAX: Introducing the Universal Live Vaccine for Infectious Bronchitis in Chickens (TW-I, TW-II), providing dual protection against respiratory and nephritis strains, precisely targeting Taiwan's prevalent local strains (TW-I, TW-II). YA SUH DAR: Launching a 50-inch butterfly shutter exhaust fan specifically designed for livestock farming. This large negative-pressure fan features an innovative pneumatic butterfly shutter design that effectively replaces traditional louver windows, significantly improving ventilation efficiency. It also offers excellent dustproof, corrosion-resistant, and weather-resistant performance, making it ideal for harsh environments with high temperatures and humidity. VETNOSTRUM: Comprehensive range of veterinary medicines, health products, feed additives, and feeds for pigs, cattle, sheep, poultry, and aquatic animals. AGRISTAR: Asia's first fully electric tractor, manufactured by Foxconn in the U.S., featuring Tesla technology and NVIDIA AI computing. Compatible with a variety of agricultural implements, it serves not only in dairy farming but also in a wide range of daily agricultural and livestock operations. This next-generation farming equipment paves the way for a net-zero carbon, sustainable agricultural future. Ms. Grace Lee, General Manager of Informa Markets Taiwan, stated: 'Taiwan's agricultural sector boasts strong technological capabilities. Through this international platform, we foster knowledge exchange and drive innovation, enhancing global food self-sufficiency where Taiwan will play an increasingly pivotal role.' The expo runs from June 11 to 13, open to industry professionals and related personnel free of charge. The organizers aim to foster cross-border collaboration and create a prosperous future for Asia-Pacific agriculture, paving the way for the next century of agricultural innovation.


Malaysian Reserve
a day ago
- Malaysian Reserve
MPF Rebuilds and Reimagines My QuitBuddy as the Nation's Leading Digital Cessation Companion
SYDNEY, June 11, 2025 /PRNewswire/ — On World No Tobacco Day, Miroma Project Factory (MPF) launched the next evolution of My QuitBuddy, Australia's flagship smoking and vaping cessation app, commissioned by the Department of Health, Disability and Ageing. The My QuitBuddy app aims to help Australians kick the habit for good. Modernised, rebuilt, and ready to support a new generation of quitters, this multi-phase redevelopment is the most significant upgrade in the app's history. MPF has led the product redesign, technical delivery, and strategic roadmap across seven structured phases – replatforming, refreshing, and relaunching a vital public health tool for the digital age. 'The My QuitBuddy app has already helped more than 1 million Australians quit smoking and vaping since it was first released in 2012, and the new developments will make it even easier for people to kick the habit,' said Mark Butler, Minister for Health, Disability and Ageing. The upgraded app is part of a suite of measures the Australian Government has put in place to tackle the health scourge of tobacco and nicotine use, particularly to support priority populations such as young people to quit smoking and vaping.' Originally launched in 2012 to support a broad range of smokers, My QuitBuddy has evolved to address broader and more complex needs, including support for people who vape. The app features stronger motivational goal setting, badges and achievements, challenges for testing situations and a more intuitive user experience; all designed to make quitting feel more achievable – and more personal. MPF was first engaged in late 2023, to reimagine the journey to be smoke/vape free, initially to restore the Android version of My QuitBuddy. This was followed by five additional phases from stabilising the app and migrating to a new environment (Flutter), which laid the foundation for a modern, cross-platform foundation without altering core functionality. Launching today marks the most transformative release that MQB has gone through. A full reimagining of the app with multiple quit pathways, advanced tracking, enhanced gamified features, dynamic onboarding, and personalised messaging for a wide range of users. 'Every click, swipe, and prompt in My QuitBuddy 2.0 is grounded in behavioural science and backed by deep user insight,' said Kat Robinson, Global CEO of MPF. 'We're not just building a better-looking app, we're building a better quit journey for every Australian.' Built for Real Impact and Reach The updated My QuitBuddy app has been shaped by years of behavioural insights, user testing, and direct feedback from the quitting community. From cravings to milestones, every screen is designed to support users when it matters most – without judgment, pressure, or gimmicks. The result is a flexible, evidence-informed platform that encourages long-term behaviour change while generating meaningful insights into user engagement, relapse patterns, and help-seeking behaviours. These insights not only guide future improvements but also provide public health teams with a clearer understanding of how different quit strategies perform across priority populations, including young vapers, dual users, and those using NRT (Nicotine Replacement Therapy) as part of their quitting strategy. Whether users are quitting cold turkey, tapering off, or using NRT, My QuitBuddy now offers them tailored support, contextual encouragement, and real-time tools to track progress, celebrate wins, prove their resilience and recover from slips. Features include: Daily motivational messages and nudges, related to your personal circumstances Richer community features and reactions, with selected featured messages Challenges you can set for yourself Games and distractions to help with cravings or withdrawal symptoms Achievements and badges that recognise how far you have come The app's new pathway selections support complex quit journeys – including simultaneous smoking and vaping cessation or staggered approaches – ensuring each user receives a personal, adaptive experience from day one. MPF now turns their efforts to continual support, enhancement, and performance monitoring. My QuitBuddy is positioned to remain a world-class cessation tool – stable, scalable, and ready to adapt with evolving policy and public health needs. Backed by MPF's long-standing partnership with the Department of Health, Disability and Aging; My QuitBuddy is more than a support app – It is a model for meaningful digital health tools, practical, evidence-based, and deeply human. DOWNLOAD ANDROID HERE DOWNLOAD IOS HERE About My QuitBuddy My QuitBuddy is a free smoking and vaping cessation app funded by the Australian Government and developed by Miroma Project Factory. Since 2012, the app has supported millions of Australians on their quit journey. Now fully rebuilt with advanced personalisation, flexible quit pathways, and updated gamified elements, My QuitBuddy is one of the most comprehensive digital cessation tools available. About Miroma Project Factory (MPF) MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, read about My QuitBuddy here. Press Contact:Miroma Project Factoryinfo@